Why do phase III clinical trials in oncology fail so often?

Journal of the National Cancer Institute

Volumn 104, Issue 8, 2012, Pages 568-569

  Amiri Kordestani, Laleh ^a   Fojo, Tito ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER THERAPY; CLINICAL TRIAL (TOPIC); EDITORIAL; HUMAN; ONCOLOGY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; SAMPLING ERROR; STATISTICAL SIGNIFICANCE; STUDY; STUDY DESIGN;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS, PHASE III AS TOPIC; HUMANS; NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84860120032     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djs180     Document Type: Editorial

References (19)

1. Collier R. Rapidly rising clinical trial costs worry researchers. CMAJ. 2009;180(3):277-278.
2. Bates SE, Amiri-Kordestani L, Giaccone G. Drug development: portals of discovery. Clin Cancer Res. 2012;18(1):23-32.
3. Gan HK, You B, Pond GR, Chen EX. Assumptions of expected benefits in randomized phase III trials evaluating systemic treatments for cancer. J Natl Cancer Inst. 2012;104(8):590-598.
4. Wu W, Shi Q, Sargent DJ. Statistical considerations for the next generation of clinical trials. Semin Oncol. 2011;38(4):598-604.
5. Hoering A, Leblanc M, Crowley JJ. Randomized phase III clinical trial designs for targeted agents. Clin Cancer Res. 2008;14(14):4358-4367.
6. Claret L, Girard P, Hoff PM, et al. Model-based prediction of phase III overall survival in colorectal cancer on the basis of phase II tumor dynamics. J Clin Oncol. 2009;27(25):4103-4108.
7. Chen TT, Chute JP, Feigal E, Johnson BE, Simon R. A model to select chemotherapy regimens for phase III trials for extensive-stage small-cell lung cancer. J Natl Cancer Inst. 2000;92(19):1601-1607.
8. Bruno R, Lu JF, Sun YN, Claret L. A modeling and simulation framework to support early clinical drug development decisions in oncology. J Clin Pharmacol. 2011;51(1):6-8.
9. Tsujino K, Shiraishi J, Tsuji T, et al. Is response rate increment obtained by molecular targeted agents related to survival benefit in the phase III trials of advanced cancer? Ann Oncol. 2010;21(8):1668-1674.
10. Buyse M, Thirion P, Carlson RW, Burzykowski T, Molenberghs G, Piedbois P. Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysis. Meta-Analysis Group in Cancer. Lancet. 2000;356(9227):373-378. (Pubitemid 30487493)
11. Pazdur R. Response rates, survival, and chemotherapy trials. J Natl Cancer Inst. 2000;92(19):1552-1553.
12. Vidaurre T, Wilkerson J, Simon R, Bates SE, Fojo T. Stable disease is not preferentially observed with targeted therapies and as currently defined has limited value in drug development. Cancer J. 2009;15(5):366-373.
13. Tolcher AW. Stable disease is a valid end point in clinical trials. Cancer J. 2009;15(5):374-378.
14. Ohorodnyk P, Eisenhauer EA, Booth CM. Clinical benefit in oncology trials: is this a patient-centred or tumour-centred end-point? Eur J Cancer. 2009;45(13):2249-2252.
15. Ocana A, Tannock IF. When are "positive" clinical trials in oncology truly positive? J Natl Cancer Inst. 2011;103(1):16-20.
16. Booth CM, Ohorodnyk P, Eisenhauer EA. Call for clarity in the reporting of benefit associated with anticancer therapies. J Clin Oncol. 2009;27(33):e213-e214.
17. Emerson SS, Fleming TR. Adaptive methods: telling "the rest of the story". J Biopharm Stat. 2010;20(6):1150-1165.
18. Chow SC, Corey R. Benefits, challenges and obstacles of adaptive clinical trial designs. Orphanet J Rare Dis. 2011;6:79.
19. Berry DA. Adaptive clinical trials in oncology. Nat Rev Clin Oncol. 2011.